![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ...
-Webcast investor event on September 14, 2024 at 9:00 a.m. ET -ESMO poster presentation to provide updated ACR-368 clinical data in endometrial cancer -Webcast to provide updates on its lead assets ACR-368, ACR-2316, and its AP3 platform WATERTOWN, Mass., …